Filament Health has shipped its patented psilocybin drug candidate PEX010 to Austin Health in Melbourne for the PSI-PHY trial, the first study to combine psilocybin-assisted physiotherapy for refractory motor functional neurological disorder (FND). Sponsored by The University of Melbourne and funded by the Australian Government, this trial explores psilocybin's potential to enhance physiotherapy by modifying brain signaling to improve motor function. This marks the first use of PEX010 in a movement disorder and highlights Filament's role as a leading supplier of pharmaceutical-grade natural psilocybin. The study could open new treatment avenues for FND, a condition with no approved drug therapies.
Pinterest director Benjamin Silbermann sold all his shares recently as the stock underperformed its market and industry peers. The stock declined 0.6% last month, lagging behind the S&P 500's 1.4% gain and the internet-software sector's 9% rise. Anal...
Applied Digital reported a fiscal Q1 2027 earnings per share of -$0.01, beating estimates of -$0.30, with revenue soaring 322% year-over-year to $341.9 million. The company is expanding its AI data center capacity internationally, securing up to 1 gi...
Sono-Tek is set to release its Q2 2027 earnings report on October 14, with analysts expecting earnings per share around $0.04-$0.05 and revenue near $5.5-$5.7 million. The company is benefiting from strong demand in the clean energy sector, recently ...
On October 7, 2026, Webull shares fell 19.2% following a congressional report raising national-security concerns over its ties to China, despite Webull's denial and assurance of U.S. data storage. Hess Midstream shares dropped 14.6% due to a transact...
On October 7, 2026, Pinnacle Food Group's stock surged 116.7% amid heavy trading volume, despite no clear company-specific news driving the rally. Other notable gainers included Armada Acquisition Corp. II, which rose 30.2% following shareholder appr...
